VOLUNTARY ANNOUNCEMENT - COMPLETION OF SUBJECT ENROLLMENT IN PHASE III CLINICAL TRIAL OF TQB2102 “HER2 BISPECIFIC ADC” FOR HER2-LOW BREAST CANCER

VOLUNTARY ANNOUNCEMENT - COMPLETION OF SUBJECT ENROLLMENT IN PHASE III CLINICAL TRIAL OF TECOTABART VEDOTIN “CLDN18.2 ADC”

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE II TRIAL OF TQA3605 "CORE PROTEIN ALLOSTERIC MODULATOR" FOR CHRONIC HEPATITIS B

CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

SHARE TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2025

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE III CLINICAL TRIAL OF TDI01 "ROCK2 INHIBITOR" FOR IDIOPATHIC PULMONARY FIBROSIS